ClinicalTrials.gg
CompletedNCT01628549Updated Feb 1, 2019Results posted

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

A Phase 2 interventional study of 50 mg P005672-HCl and Placebo in Acne Vulgaris, sponsored by Almirall, S.A.. Completed at 38 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Almirall, S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
106th of 353
285 · median 78
Started
2012
with 13 others
Phase 2
65 of 373
none open now
Registered
117th of 373
by date
Lead sponsor
8 of 373
Almirall, S.A.

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 106th largest by enrollment of the 353 interventional ones that give a count, is one of 14 that started in 2012, is one of 65 in phase 2, and was the 117th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • if women of , have a negative urine pregnancy test
  • Willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study
  • Male or female, 12-45 years of age with body weight between 52 and 88 kg
  • Diagnosis of acne vulgaris with:

    20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)

  • No more than 2 nodules on the face
  • Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)

Exclusion criteria

Exclusion Criteria:

  • Dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible:

Within 1 week prior to randomization:

  • Medicated facial cleansers
  • Topical acne treatments (other than those listed below)

Within 4 weeks prior to randomization:

  • Topical retinoids
  • Topical anti-inflammatories and
  • Systemic antibiotics
  • Systemic acne treatments

Within 12 weeks prior to randomization:

  • Systemic retinoids
  • Systemic corticosteroids
  • Pseudomembranous colitis or antibiotic-associated colitis
  • Hepatitis, liver damage or renal impairment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    P005672-HCl approximately 0.75 mg/kg/day

    One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks

    Drug: 50 mg P005672-HCl · Drug: Placebo

  • Experimental
    P005672-HCl approximately 1.5 mg/kg/day

    Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks

    Drug: 50 mg P005672-HCl

  • Experimental
    P005672-HCl approximately 3.0 mg/kg/day

    Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks

    Drug: 100 mg P005672-HCl

  • Placebo comparator
    Placebo

    Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks

    Drug: Placebo

Interventions

  • Drug50 mg P005672-HCl

    P005672-HCl administered as an oral capsule(s) once daily

    Also known as: WC3035, Sarecycline

  • DrugPlacebo

    Dose-matched Placebo capsule administered as an oral capsule(s) once daily

    Also known as: Inactive

  • Drug100 mg P005672-HCl

    P005672-HCl administered as an oral capsule(s) once daily

    Also known as: WC3035, Sarecycline

06

What researchers measure

Primary outcomes

  1. The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit

    Time frame: Baseline (Week 0) to Final Visit (Up to Week 12)

  2. The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit

    The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.

    Time frame: Final Visit (Up to Week 12)

Secondary outcomes

  1. The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit

    Time frame: Baseline (Week 0) up to Week 12

  2. The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit

    Time frame: Baseline (Week 0) up to Week 12

  3. The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit

    Time frame: Baseline (Week 0) up to Week 12

  4. The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit

    Time frame: Baseline (Week 0) up to Week 12

  5. The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12

    The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.

    Time frame: Baseline to Final Visit (Up to Week 12)

07

Results

Posted Jan 8, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Started73767066
Completed64646057
Not completed912109
Withdrew: Adverse event1104
Withdrew: Lost to follow-up3433
Withdrew: Withdrawal by subject3441
Withdrew: Protocol violation2110
Withdrew: Withdrawn for noncompliance0210
Withdrew: Abnormal laboratory test results0010
Withdrew: Positive pregnancy test0001

Outcome measures

PrimaryThe Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit
Time frame:
Baseline (Week 0) to Final Visit (Up to Week 12)
Reported as:
Mean · Number of Inflammatory Lesions
The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit
Number of Inflammatory LesionsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit12.8 ± 14.1814.4 ± 13.0117.6 ± 16.6517.1 ± 11.69
Statistical analysis
  • Placebo vs P005672-HCl Approximately 0.75 mg/kg/Day · ANCOVA · p = 0.4344 · Difference in least squares means: 1.53 · 95% CI -2.32 to 5.38
  • Placebo vs P005672-HCl Approximately 1.5 mg/kg/Day · ANCOVA · p = 0.0266 · Difference in least squares means: 4.46 · 95% CI 0.52 to 8.40
  • Placebo vs P005672-HCl Approximately 3.0 mg/kg/Day · ANCOVA · p = 0.0317 · Difference in least squares means: 4.37 · 95% CI 0.39 to 8.36
PrimaryThe Dichotomized IGA (Investigator Global Assessment) Score at Final Visit

The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.

Time frame:
Final Visit (Up to Week 12)
Reported as:
Count of participants · Participants
The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit
ParticipantsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Success8111710
Failure64655356
Statistical analysis
  • Placebo vs P005672-HCl Approximately 0.75 mg/kg/Day · Cochran-Mantel-Haenszel · p = 0.3300 · Difference vs placebo in success rate: 3.4 · 95% CI -7.82 to 14.38
  • Placebo vs P005672-HCl Approximately 1.5 mg/kg/Day · Cochran-Mantel-Haenszel · p = 0.0159 · Difference vs placebo in success rate: 13.2 · 95% CI 0.54 to 25.60
  • Placebo vs P005672-HCl Approximately 3.0 mg/kg/Day · Cochran-Mantel-Haenszel · p = 0.4834 · Difference vs placebo in success rate: 4.1 · 95% CI -7.44 to 15.87
SecondaryThe Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit
Time frame:
Baseline (Week 0) up to Week 12
Reported as:
Mean · Count of Inflammatory Lesions
The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit
Count of Inflammatory LesionsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Change from Baseline at Week 15.8 ± 9.075.4 ± 9.285.4 ± 8.445.9 ± 8.33
Change from Baseline at Week 28.4 ± 10.138.5 ± 10.028.2 ± 14.459.7 ± 11.30
Change from Baseline at Week 410.9 ± 10.049.3 ± 13.8411.7 ± 15.3612.8 ± 9.96
Change from Baseline at Week 812.6 ± 12.5713.1 ± 11.8915.0 ± 16.6614.3 ± 12.90
Change from Baseline at Week 1212.8 ± 14.1814.3 ± 13.0017.6 ± 16.6517.1 ± 11.69
Change from Baseline at Final Visit(Up to Week 12)12.8 ± 14.1814.4 ± 13.0117.6 ± 16.6517.1 ± 11.69
SecondaryThe Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame:
Baseline (Week 0) up to Week 12
Reported as:
Mean · Count of Noninflammatory Lesions
The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Count of Noninflammatory LesionsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Change from Baseline at Week 15.4 ± 12.993.8 ± 14.284.3 ± 14.105.1 ± 13.83
Change from Baseline at Week 210.6 ± 16.029.4 ± 13.587.8 ± 16.927.9 ± 14.24
Change from Baseline at Week 413.0 ± 24.1710.0 ± 17.259.9 ± 20.5812.7 ± 15.24
Change from Baseline at Week 816.9 ± 22.5214.3 ± 21.4414.0 ± 22.2215.2 ± 19.04
Change from Baseline at Week 1217.8 ± 21.6317.9 ± 19.8519.1 ± 22.3317.0 ± 21.56
Change from Baseline at Final Visit(Up to Week 12)17.8 ± 21.6317.9 ± 19.8319.1 ± 22.3317.0 ± 21.56
SecondaryThe Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame:
Baseline (Week 0) up to Week 12
Reported as:
Mean · Percent Change - Inflammatory Lesions
The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Percent Change - Inflammatory LesionsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Change from Baseline at Week 119.3 ± 27.8217.2 ± 28.4317.8 ± 26.3919.4 ± 26.17
Change from Baseline at Week 225.6 ± 29.0226.4 ± 32.6025.8 ± 36.1630.6 ± 35.88
Change from Baseline at Week 434.1 ± 28.8429.3 ± 38.9034.1 ± 35.2740.0 ± 31.83
Change from Baseline at Week 837.9 ± 35.6039.8 ± 34.4744.3 ± 37.9944.5 ± 37.62
Change from Baseline at Week 1239.1 ± 43.0043.3 ± 39.7053.6 ± 37.6553.5 ± 35.18
Change from Baseline at Final Visit(Up to Week 12)39.1 ± 43.0043.5 ± 39.7253.6 ± 37.6553.5 ± 35.18
SecondaryThe Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame:
Baseline (Week 0) up to Week 12
Reported as:
Mean · Percent change - noninflammatory lesions
The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Percent change - noninflammatory lesionsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Change from Baseline at Week 19.7 ± 24.077.7 ± 26.878.3 ± 25.2010.6 ± 25.63
Change from Baseline at Week 219.0 ± 28.3616.7 ± 24.9914.6 ± 30.5716.0 ± 30.37
Change from Baseline at Week 425.0 ± 37.7818.3 ± 33.1719.2 ± 35.6025.7 ± 29.27
Change from Baseline at Week 830.5 ± 40.6926.1 ± 38.8427.5 ± 38.5430.4 ± 38.45
Change from Baseline at Week 1235.3 ± 35.3234.3 ± 36.4037.2 ± 38.4432.8 ± 42.59
Change from Baseline at Final Visit(Up to Week 12)35.3 ± 35.3234.1 ± 36.2837.2 ± 38.4432.8 ± 42.59
SecondaryThe Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12

The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.

Time frame:
Baseline to Final Visit (Up to Week 12)
Reported as:
Count of participants · Participants
The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12
ParticipantsPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
Week 1 — Success0301
Week 1 — Failure72737065
Week 2 — Success2322
Week 2 — Failure70736864
Week 4 — Success1204
Week 4 — Failure71747062
Week 8 — Success66811
Week 8 — Failure66706255
Week 12 — Success8111710
Week 12 — Failure64655356
Final Visit (Up to Week 12) — Success8111710
Final Visit (Up to Week 12) — Failure64655356

Adverse events

Collected over From Screening (up to week -12) to Week 12 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/73 (0%)13/73 (17.8%)
P005672-HCl Approximately 0.75 mg/kg/Day—0/76 (0%)15/76 (19.7%)
P005672-HCl Approximately 1.5 mg/kg/Day—0/70 (0%)8/70 (11.4%)
P005672-HCl Approximately 3.0 mg/kg/Day—0/66 (0%)7/66 (10.6%)
Most frequent other events
Most frequent other events
EventPlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/Day
HeadacheNervous system disorders8/735/765/704/66
NauseaGastrointestinal disorders4/736/761/702/66
NasopharyngitisInfections and infestations5/734/762/702/66

Baseline characteristics

285 participants were randomized to double-blind treatment (Safety population)

Age, Continuous
Age, Continuous(Years)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
Mean20.8 ± 6.9919.7 ± 5.9219.9 ± 7.0420.3 ± 7.1120.2 ± 6.74
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
Male25293029113
Female48474037172
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
Hispanic or Latino1921161975
Not Hispanic or Latino54555447210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
American Indian or Alaska Native10012
Asian443112
Black or African American1718211369
Native Hawaiian or Other Pacific islander00000
White54554652207
Height
Height(cm)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
Mean165.80 ± 10.436167.49 ± 9.047167.23 ± 7.380167.33 ± 9.764166.96 ± 9.206
Weight at Baseline
Weight at Baseline(kg)PlaceboP005672-HCl Approximately 0.75 mg/kg/DayP005672-HCl Approximately 1.5 mg/kg/DayP005672-HCl Approximately 3.0 mg/kg/DayTotal
Mean68.47 ± 10.30666.37 ± 8.74969.69 ± 11.86167.31 ± 9.48667.94 ± 10.173
08

Study locations

38 sites
  • Warner Chilcott Investigational Site
    Mobile, Alabama 36608, United States
  • Warner Chilcott Investigational Site
    Tucson, Arizona 85710, United States
  • Warner Chilcott Investigational Site
    Hot Springs, Arkansas 71913, United States
  • Warner Chilcott Investigational Site
    Los Angeles, California 90045, United States
  • Warner Chilcott Investigational Site
    San Diego, California 92123, United States
  • Warner Chilcott Investigational Site
    Santa Monica, California 90404, United States
  • Warner Chilcott Investigational Site
    Clearwater, Florida 33761, United States
  • Warner Chilcott Investigational Site
    Coral Gables, Florida 33134, United States
  • Warner Chilcott Investigational Site
    Gainesville, Florida 32605, United States
  • Warner Chilcott Investigational Site
    Miami, Florida 33175, United States
  • Warner Chilcott Investigational Site
    Miramar, Florida 33027, United States
  • Warner Chilcott Investigational Site
    Pinellas Park, Florida 33781, United States
  • Warner Chilcott Investigational Site
    Arlington Heights, Illinois 60005, United States
  • Warner Chilcott Investigational Site
    Chicago, Illinois 60611, United States
  • Warner Chilcott Investigational Site
    Granger, Indiana 46530, United States
  • Warner Chilcott Investigational Site
    Indianapolis, Indiana 46256, United States
  • Warner Chilcott Investigational Site
    Louisville, Kentucky 40202, United States
  • Warner Chilcott Investigational Site
    Boston, Massachusetts 02135, United States
  • Warner Chilcott Investigational Site
    Fridley, Minnesota 44532, United States
  • Warner Chilcott Investigational Site
    Saint Louis, Missouri 63117, United States
  • Warner Chilcott Investigational Site
    Berlin, New Jersey 08009, United States
  • Warner Chilcott Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Warner Chilcott Investigational Site
    Rochester, New York 14609, United States
  • Warner Chilcott Investigational Site
    Rochester, New York 14623, United States
  • Warner Chilcott Investigational Site
    Charlotte, North Carolina 28209, United States
  • Warner Chilcott Investigational Site
    Salisbury, North Carolina 28144, United States
  • Warner Chilcott Investigational Site
    Wilmington, North Carolina 28401, United States
  • Warner Chilcott Investigational Site
    Cincinnati, Ohio 45249, United States
  • Warner Chilcott Investigational Site
    Portland, Oregon 97210, United States
  • Warner Chilcott Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Warner Chilcott Investigational Site
    Greer, South Carolina 29650, United States
  • Warner Chilcott Investigational Site
    Arlington, Texas 76011, United States
  • Warner Chilcott Investigational Site
    Austin, Texas 78759, United States
  • Warner Chilcott Investigational Site
    Houston, Texas 77065, United States
  • Warner Chilcott Investigational Site
    Plano, Texas 75093, United States
  • Warner Chilcott Investigational Site
    San Antonio, Texas 78229, United States
  • Warner Chilcott Investigational Site
    Sandy, Utah 84070, United States
  • Warner Chilcott Investigational Site
    Lynchburg, Virginia 24501, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Nov 2012, 4 months.

Results were first posted in Jan 2019, 6 years 1 month after primary completion. A results delay was requested in Dec 2013.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2012
First posted
Jun 26, 2012
StartActual
Jun 30, 2012
Primary completionActual
Nov 16, 2012
CompletionActual
Jan 31, 2013
Results delay requested
Dec 11, 2013
Results first posted
Jan 8, 2019
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01628549
Lead sponsor
Almirall, S.A.
Collaborators
Allergan
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
Jun 30, 2012
Primary completion
Nov 16, 2012
Completion
Jan 31, 2013
Results posted
Jan 8, 2019
Last update
Feb 1, 2019

Study contacts

Herman Ellman, MD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion